Introduction to the European Society for Antiviral Resistance (ESAR)
Mission of ESAR Bring together scientists and clinicians (Europe) in order to develop activities to study, treat and drug (HIV) resistant viruses, this all in the broadest sense of the word.
Reasons for ESAR Resulting from two successful EC • projects Extending collaborations • • restricted number of partners • limited amount of participating centers per country EuropeHIVResistance
Objectives ESAR Improve knowledge • Improve diagnostic strategies • Improve the clinical management of resistant • viruses Monitor public health threads •
Activities ESAR SPREAD ‐ surveillance programme • Collaborative network for scientific studies • Knowledge Platform • Guidelines • Exchange of information • Training activities • Improving diagnostic strategies: QC ‐ programmes •
Principles of ESAR Collaboration • Responsibility towards science and society • Transparency • Independency • Flexibility •
Formal Society Non ‐ profit organisation • By ‐ laws will be made available on ESAR website •
Membership Associated (voting) membership is individual and open to scientists and clinicians who share the Aims of the Society. Members per country vote for 2 council members. From the council a board is composed.
Membership (non voting) Non ‐ Associated Members working for • commercial organisations Student Members •
Benefits of Membership • Opportunity to be involved in collaborative projects with a well established and well organised, very productive group of people representing whole of Europe • Opportunity to shape our scientific agenda • Access to dedicated Members' Zone ESAR website • ESAR newsletter
Boardmembers • Charles Boucher (Chairman) • Annemarie Wensing (Executive Officer) • Leon Kostrikis (Treasurer) • Jan Albert • Bonaventura Clotet • Osamah Hamouda • Andrzej Horban • Dan Otelea • Mario Poljak • Jean ‐ Claude Schmit • Annemie Vandamme
Council members I Austria Cyprus 1. Elisabeth Puchhammer ‐ To be nominated 2. Benedikt Simon Czech Republic Belgium ‐ To be nominated 1. Linos Vandekerkchove 2. To be nominated Denmark 1. Louise Bruun Jørgensen Bulgaria 2. Jan Gerstoft 1. Danail Beshkov 2. Ivailo Alexiev Ivanov Estonia 1. Kai Zilmer Croatia 2. Kristi Huik 1. Snjezana Zidovec Lepej 2. Josip Begovac Finland 1. Kirsi Liitsola 2. To be nominated
Council members II France Israel ‐ To be nominated 1. Zehava Grossman 2. Itzchk Levy Germany 1. Klaus Korn Italy 2.To be nominated ‐ To be nominated Greece Latvia 1. Dimitrios Paraskevis ‐ To be nominated 2. Mina Psichogiou Lithuania Hungary ‐ To be nominated ‐ To be nominated Luxembourg Ireland 1. Danielle Perez ‐ Bercoff 1. Suzie Coughlan 2. Daniel Struck 2. Cillian de Gascun
Council members III Netherlands Romania 1. Rob Schuurman 1. Simona Paraschiv 2. To be nominated 2. Ana Maria Tudor Norway Russia 1. Birgitta Asjo 1. Natalaya Ladnaya 2. Halvor Rollag 2. Dmitry Kuevda Poland Serbia 1. Janusz Stanczak 1. Maja Stanojevic 2. To be nominated 2. To be nominated Portugal Slovakia 1. Ricardo Camacho 1. Danica Stanekova 2. Eugénio Teófilo 2. To be nominated
Council members IV Slovenia United Kingdom 1. Janez Tomazic 1. Annemaria Geretti 2. Katja Seme 2. To be nominated Spain 1. Roger Paredes 2. To be nominated Sweden 1. Anders Sonnerborg 2. To be nominated Switzerland ‐ To be nominated
Membership fee SPECIMEN SPECIMEN Contributional year March 1 – February 28/29 Fee 2011/2012 10 Euro Payment ‐ via registration EDRW ‐ via invoice
ESAR Meetings Annual Scientific Meeting preceeding the • European HIV & Hepatitis Workshop General meeting: Board and Council members •
Communication Structure www.ESAR ‐ Society.eu Email:info@ESAR ‐ Society.eu
Recommend
More recommend
